Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS6265413 B1
Publication typeGrant
Application numberUS 08/860,655
PCT numberPCT/KR1996/000004
Publication dateJul 24, 2001
Filing dateJan 9, 1996
Priority dateJan 9, 1995
Fee statusPaid
Also published asCA2208639A1, CA2208639C, CN1077575C, CN1168139A, DE69625176D1, DE69625176T2, EP0802915A1, EP0802915B1, US6177568, WO1996021666A1
Publication number08860655, 860655, PCT/1996/4, PCT/KR/1996/000004, PCT/KR/1996/00004, PCT/KR/96/000004, PCT/KR/96/00004, PCT/KR1996/000004, PCT/KR1996/00004, PCT/KR1996000004, PCT/KR199600004, PCT/KR96/000004, PCT/KR96/00004, PCT/KR96000004, PCT/KR9600004, US 6265413 B1, US 6265413B1, US-B1-6265413, US6265413 B1, US6265413B1
InventorsSang Sup Jew, Hee Soon Lee, Joon Kyum Kim, Kwang Dae Ok, Kyeong Hoi Cha, Myoung Goo Kim, Kwang Kyun Lee, Jong Min Kim, Hee Jin Kim, Jeong Mi Hah
Original AssigneeChong Kun Dang Corp.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Camptothecin compounds and a method of preparation thereof
US 6265413 B1
Abstract
Camptothecin derivatives and pharmaceutically acceptable salts thereof, its manufacturing method and an antineoplastic agent containing it. The camptothecin derivatives are modified in B-ring and E-ring and show improved water solubility and enhanced antineoplastic effect.
Images(2)
Previous page
Next page
Claims(3)
What is claimed is:
1. A camptothecin compound of the formula I, or a pharmaceutically acceptable salt thereof
wherein:
R is hydrogen or −(CH2)2—NR1R2, where R1 is hydrogen or an amino protecting group and R2 is a lower alkyl, hydroxyethyl or acetoxyethyl group, or R1 and R2, together with the nitrogen atom to which they are attached, form a cyclic moiety;
n is 1 or 2; and
R3 is hydrogen or −OR4, where R4 is hydrogen, COR5, CONHR6, or CH2OR7, where R5 is methyl or CH3OCH2—, R6 is isopropyl, phenyl or —CH2CH2Cl and R7 is methyl, ethyl, or CH3OCH2CH2—;
with the provisos that:
R and R3 cannot both be hydrogen;
when n is 2 and R is —(CH2)2—N(Cbz)CH3, then R3 cannot be hydrogen;
when n is 2 and R3 is OH, then R cannot be hydrogen; and
when R is —CH2CH2NHCH3, then R3 cannot be hydrogen.
2. An antineoplastic composition containing a camptothecin compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier
wherein:
R is hydrogen or —(CH2)2—NR1R2, where R1 is hydrogen or an amino protecting group and R2 is a lower alkyl, hydroxyethyl or acetoxyethyl group, or R1 and R2, together with the nitrogen atom to which they are attached, form a cyclic moiety;
n is 1 or 2; and
R3 is hydrogen or —OR4, where R4 is hydrogen, COR5, CONHR6, or CH2OR7, where R5 is methyl or CH3OCH2—, R6 is isopropyl, phenyl or —CH2CH2Cl and R7 is methyl, ethyl, or CH3OCH2CH2—;
with the provisos that:
R and R3 cannot both be hydrogen;
when n is 2 and R is —(CH2)2—N(Cbz)CH3, then R3 cannot be hydrogen;
when n is 2 and R3 is OH, then R cannot be hydrogen; and
when R is —CH2CH2NHCH3, then R3 cannot be hydrogen.
3. A process for manufacturing a compound of the formula I by reacting a compound of the formula II with a compound of the formula III under acidic conditions
wherein:
R′ is hydrogen or −(CH2)2—NR1R2, where R1 is an amino protecting group and R2 is a lower alkyl, hydroxyethyl or acetoxyethyl group, or R1 and R2, together with the nitrogen atom to which they are attached, form a cyclic moiety;
P is hydrogen or —(CH2)2—NR1R2, where R1 is hydrogen or an amino protecting group and R2 is a lower alkyl, hydroxyethyl or acetoxyethyl group, or R1 and R2, together with the nitrogen atom to which they are attached, form a cyclic moiety;
n is 1 or 2; and
R3 is hydrogen or —OR4, where R4 is hydrogen, COR5, CONHR6, or CH2OR7, where R5 is methyl or CH3OCH2—, R6 is isopropyl, phenyl or —CH2CH2Cl and R7 is methyl, ethyl, or CH3OCH2CH2—;
with the provisos that:
R and R3 cannot both be hydrogen;
when n is 2 and R is —(CH2)2—N(Cbz)CH3, then R3 cannot be hydrogen;
when n is 2 and R3 is OH, then R cannot be hydrogen; and
when R is —CH2CH2NHCH3, then R3 cannot be hydrogen.
Description
TECHNICAL FIELD

This invention relates to camptothecin derivatives and pharmaceutically acceptable salts thereof, expressed by the following chemical formula (I), its manufacturing method and antineoplastic agent containing it as an active ingredient

Wherein;

R is hydrogen or —(CH2)2—NR1R2, (R1 is hydrogen or a general protecting group of amine; R2 is a lower alkyl, hydroxyethyl or acetoxyethyl; further, R2 may form heterocyclic compound by binding with an adjacent nitrogen);

n is 1 or 2; R3 is hydrogen or —OR4 [R4 is hydrogen or

(R5 is methyl or CH3OCH2—);

(R6 is isopropyl, phenyl or —CH2CH2Cl.); CH2OR7 (R7 is methyl, ethyl or CH3OCH2CH2—)];

Wherein;

When n is 2 and R4 is hydrogen, R is not hydrogen;

and when n is 2 and R3 is H, R is not hydrogen;

also, when R is —CH2CH2NHCH3, R3 is not hydrogen.

BACKGROUND OF ART

Since the isolation of camptothecin from the Chinese tree, Camptotheca acuminata, by Wall and co-workers (J. Am. Chem. Soc., 1966, 88, 3888), there had been many approaches to synthesize camptothecin. However, the development of camptothecin as an effective antineoplastic agent was unsuccessful due to its severe toxicity in the first clinical trial in 1970.

Thereafter, Liu et al. reported in 1985 that camptothecin had a specific mode of action to inhibit topoisomerase I. Thus, considerable interest has focused on this compound. In particular, since topoisomerase I inhibitor itself was not used clinically, it is expected that with its actual development, camptothecin may be very efficiently used in combination with other antineoplastic chemotherapeutics having different modes of action.

Recently, various studies for the development of camptothecin derivatives have been proposed in order to reduce the toxicity of camptothecin and to further enhance its antineoplastic activities. Among these related studies, the clinical trial of CPT-11 (Irinotecan) synthesized by Yakurt-Honsha Co. of Japan in 1986 showed that it exhibited excellent antineoplastic activities with less toxicity (Japanese Patent Laid Open Publication No. 64-61482) and followed by other pharmaceutical companies such as Smithkline Beecham (Topotecan) and Glaxo (MDO-camptothecin and 9-aminocamptothecin). Among them, CPT-11 is launched. In particular, it is noticeable that said CPT-11 compound has exhibited excellent antineoplastic activities in the treatment of incurable solid tumors such as the lung cancer.

Since a majority of camptothecin derivatives developed hitherto were semi-synthetic compounds which were obtained from the chemical modification of camptothecin, there were some difficulties in procuring camptothecin and in developing derivatives with a variety of structures because of restrictions of said chemical modification. In addition, these reported total synthesis are not satisfactory in view of both chemical and optical yields.

DISCLOSURE OF INVENTION

Accordingly, the inventor et al. have confirmed that through the total synthesis for a series of novel compounds expressed by said general formula (I) and followed by in vitro test, these compounds with different mode of action may be used as effective antineoplastic agents. Thus, the present invention has been completed.

Camptothecin is a fused ring system, composed of a quinoline (A and B), fused to a pyrrolidine ring (C), fused to an alpha-pyridone ring (D) which in turn is fused to a lactone ring(E).

In particular, further careful review has been made on camptothecin's mode of action to inhibit topoisomerase I and various structures of camptothecin derivatives developed hitherto, and attempts have been also made in such a manner to modify the substituents of B-ring or E-ring in camptothecin.

In consideration of the fact that the conventionally developed derivatives have suffered from some side effects such as nausea, vomiting and cystitis due to extremely poor water solubility, the introduction of side chain at B-ring of camptothecin was made in such a manner that in order to enhance the solubility. Hence, the side chain including amino groups was introduced at the 7-position of camptothecin.

In view of the mode of action suggested by Crow that camptothecin binds covalently with topoisomerase I [J. Med. Chem., 1992, 35, 4160-4164], the modification of camptothecin at E-ring was attempted so as to enhance its reactivity.

The processes for manufacturing camptothecin derivatives and its intermediates are described in more detail as set forth hereunder, in accordance with the practice of this invention.

The compounds based upon EXAMPLES can be prepared in accordance with the practice of this invention as specified in the following Scheme 1.

Wherein;

R, n and R3 are the same as described in the above and R′ is hydrogen or —(CH2)2—NR1R2; R1 is a general protecting group of amine; R2 is the same as described in the above. Friedlander condensation of aminoketone compound (II) with tricyclic Ketone (III) affords the compound expressed by the general formula (I) [organic reactions, 28, 37-202, Wiley & Sons Inc, New York (1932)].

The condensation of the compounds (II) and (III) is conducted, in general, in the presence of acid at room temperature or under the heating condition.

The following inert solvents should be used for the reactions so as not to affect the reactions, for example, aromatic hydrocarbons(toluene, benzene, xylene etc.), hydrocarbon halide(dichloromethane, chloroform, 1,1-dichloroethane, 1,2-dichoroethane etc.), lower alcohols, amides (N,N-dimethylformamide etc.), or acetic acid.

The reactions may be conducted using inorganic acid(hydrochloric acid or sulfuric acid) or organic acids (methanesulfonic acid, trifluoromethanesulfonic acid, ρ-toluenesulfonic acid, acetic acid, etc.).

The reaction time ranges from 1 to 48 hrs, and the reaction temperature is 30 to 150° C.

As a typical reaction condition, it is most preferable that reflux is made available in the presence of ρ-toluenesulfonic acid in toluene.

When R is —CH2CH2NHR2 (R1 is hydrogen) in the synthesis of general formula (I), said amino protecting group is removed through the catalytic hydrogenation using platinum or palladium.

When R′ is hydrogen in the compound (II), compound(I) is obtained after carbonyl group of the compound(II) is protected by acetalization with ethylene glycol or by formation of shiff base with ρ-toluidine according to known process. [Chem. Ber. 76, 1099(1943)].

When R3 is hydroxy group in the compound (III), thus obtained compound(I), wherein R3 is hydroxy group, is reacted with such reagents as

and R7OCH2Cl to produce the compound(I) wherein the hydroxy group of R3 is thus modified.

In particular, when R6NCO is used, the compound expressed by the general formula (I) can be obtained by using the catalytic amounts of tin complex (e.g., di-n-butyltin diacetate, etc.).

The aminoketone (II) can be prepared in accordance with Scheme 2.

Wherein;

R′, R1 and R2 are the same as described in the above.

A novel aminoketone compound (II) of this invention can be prepared as follows:

2′-nitroacetophenone reacts with monoalkylamine (e.g., ethylamine, propylamine or isopropylamine), monoarylamine (e.g., benzylamine) or dialkylamine (e.g., morpholine, piperidine or diethylamine) in the presence of conc. hydrochloric acid, through Mannich reaction with paraformaldehyde to give the compound(IV).

The reaction is conducted at 30-80C for 1 to 48 hrs.

In case of the compound (IV) having monoalkylamine or monoarylamine, the general protecting group of amine is introduced to give the said compound (IV).

According to this invention, Cbz (carbobenzyloxy) is a preferable protecting group of amine.

The compound (IV) is treated with sodium dithionite in lower alcohol solvent to give the compound (II).

The reaction is conducted at 30 to 100° C. for 1 to 10 hrs.

As specified in Scheme 3 below, a novel tricyclic ketone (III) of this invention can be prepared from the compound (IX) which is already known.

From the compound (III), tricyclicketone (n is 2 and R3 is H) is already known compound prepared in accordance with a convention method (U.S. Pat. No. 4,894,456 (1990)).

Wherein;

R3T n, R5 and R6 are the same as described in the above and R8 is the general protecting group of hydroxyl group.

During α-alkylation re action where n is 2, the compound (IX) reacts with base such as KOtBu or NaH in inert solvent including N, N-dimethylformamid or 1,2-dimethoxyethane. Then, the reaction mixture is reacted with 2-bromoethanol protected with tetrahydropyranyl, methoxymethyl or methoxyethoxymethyl to give the compound (VIII).

The reaction is preferably conducted at 30 to 60° C. for 18 to 48 hrs.

Meanwhile, when n is 1, α-hydroxymethylation is conducted using formaldehyde in alcoholic solvent and followed by the protection with the general protecting group of OH to give the compound(VIII).

The preferable protecting group of this invention is methoxymethyl or methoxyethoxymethyl.

The compound (VII) was obtained by the reduction of compound (VIII) using Raney-Nickel as a catalyst in a cosolvent of acetic acid and acetic anhydride.

The reaction is conducted at 30 to 80° C. for 1 to 10 hrs.

The rearrangement via nitroso compound is done by reacting the compound (VII) with sodium nitrite in a co-solvent of acetic anhydride and acetic acid at 0 to 50° C. for 1 to 24 hrs. Thus, obtained nitroso compound is refluxed in the solvent such as CCl4 at 60 to 90° C. for 5 to 18 hrs to give the compound (VI).

When n is 1 or 2, the reaction route of the diester (VI) becomes slightly different. In case that n is 2, compound(VI) is hydrolyzed in alkali aqueous solution including LiOH, NaOH and KOH in methanol and treated with acidic aqueous solution such as acetic acid or hydrochloric acid to give the compound (Vc).

Said hydrolysis is conducted at 0 to 50° C. for 30 mins to 5 hrs.

The lactonization in acidic aqueous solution is conducted at 0 to 50° C. for 1 to 48 hrs.

Compound (Vc) is treated with base such as potassium t-butoxide in the amine solvents such as N,N-dimethylformamide or N,N-dimethylacetamide and oxidized with the bubbling of O2 under triethylphosphite to give the compound (V).

The reaction is conducted at −10 to 50° C. for 30 mins to 5 hrs.

Meanwhile, when n is 1, compound(VI) is treated with organic base such as DBU, DBN or triethylamine in aromatic hydrocarbon solvent such as benzene, toluene or xylene to produce the compound (Va).

The reaction is conducted at 0° C. to 100° C. for 10 mins to 5 hrs.

The compound (Va) is treated with OsO4 in a pyridine solvent to give the compound (Vb). This reaction is conducted at 10 to 50° C. for 1 to 10 hrs. The lactonization of the compound (Vb) is carried out as the same as described in the above.

The compound (V) where n is 2, is treated with acid to produce compound (III). The reaction is conducted at 10 to 80° C. for 30 mins to 10 hrs. In case of the compound (V) wherein n is 1, said deketalization is done after introducing the substituent by treating

for the preparation of the compound (III).

In case of the compound (I) of this invention where R is CH2CH2NR1R2, the conversion of secondary amine into the salts of inorganic acids (e.g., hydrochloric acid, sulfuric acid, phosphoric acid, etc.) or organic acids (e.g., acetic acid) makes it possible to prepare physiologically acceptable salts.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 illustrates the difference of ILS(%) in various dose between the compound prepared in example 30 and camptothecin.

FIG. 2 illustrates the inhibitory effects on mice melanorma cells in accordance with the compound prepared in example 30.

BEST MODE FOR CARRYING OUT THE INVENTION

This invention is explained in more detail by the following examples and experiments, but the claims are not limited to these examples and experiments.

EXAMPLES 1

Preparation of 3-morpholino-1-(2′-nitrophenyl)propan-1-one

A solution of morpholine (2.27 g, 0.026 mol) in ethanol (10 ml) was treated with c-HCl (3 ml) for 10 mins, concentrated under reduced pressure to prepare morpholine HCl salt. To this mixture, 2′-nitroacetophenone (3.3 g, 0.02 mol), paraformaldehyde (0.8 g, 0.029 mol), c-HCl (0.1 ml) and anhydrous ethanol (10 ml) were added. The reaction mixture was stirred under reflux for 30 hrs. This reaction mixture was then cooled to room temperature, alkalized with 10% sodium carbonate solution, and the reaction mixture was extracted with dichloromethane(3×50 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product. The crude product was purified by flash column chromatography with 5% ethanol in dichloromethane to give the desired product (1.5 g, 35%) as an oil.

1H-NMR (CDCl3) δ 3.1 (m, 3H), 3.5 (m, 4H), 3.75 (m, 3H), 3.99 (m, 2H), 7.85 (m, 3H), 8.15 (d, 1H, J=8 Hz)

EXAMPLE 2

Preparation of 3-piperidino-1-(2′-nitrophenyl) propan-1-one

In the same procedure as in EXAMPLE 1, the desired product (458 mg, 29%) was yielded using piperidine (515 mg, 6.06 mmol), 2′-nitroacetophenone (1 g, 6.06 mmol), paraformaldehyde (260 mg, 8.67 mmol); c-HCl (1 ml) and anhydrous ethanol.

1H-NMR (CDCl3) δ 1.5 (m, 6H), 2.38 (t, 4H, J=5 Hz), 2.76 (t, 2H, J=6 Hz), 3.00 (t, 2H, J=6 Hz), 3.99 (m, 2H), 7.40-7.75 (m, 3H), 8.13 (d, 1H, J=8 Hz)

EXAMPLE 3

Preparation of 3-pyrrolidino-1-(2′-nitrophenyl) propane-1-one

In the same procedure as in EXAMPLE 1, the desired product (347 mg, 23%) was yielded using pyrrolidine (560 mg, 7.88 mmol), 2′-nitroacetophenone (1 g, 6.06 mmol), paraformaldehyde (260 mg, 8.67 mmol), c-HCl (1 ml) and anhydrous ethanol (5 ml).

EXAMPLE 4

Preparation of 3-(N-benzyl-N-carbobenzyloxyamino)-1-(2′-nitrophenyl)propane-1-one

A solution of benzylamine (2.79 g, 0.026 mol) in ethanol (10 ml) was treated with c-HCl (3 ml) for 10 min, concentrated under reduced pressure to prepare benzylamine·HCl salt.

To this solution, 2′-nitroacetophenone (3.3 g, 0.02 mol), paraformaldehyde (800 mg, 0.029 mol), c-HCl (0.1 ml) and anhydrous ethanol (10 ml) were added.

The reaction mixture was stirred under reflux for 30 hrs. This reaction mixture was then cooled to room temperature, alkalized with 10% sodium carbonate solution, and the reaction mixture was extracted with dichloromethane (3×50 ml) The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give the crude product, which was dissolved in dichloromethane and cooled to 0° C. To this mixture, triethylamine (1.2 g, 0.012 mol) was added and followed by another dropwise addition of benzylchloroformate (2 ml). The reaction mixture was stirred under nitrogen flow at 0° C. for 1 hr, heated to room temperature and then stirred for additional 5 hrs.

After removing the solvent under reduced pressure, the mixture was dissolved in ethylacetate (100 ml). The organic layer was washed with water (3×30 ml) and brine (30 ml) and dried over anhydrous sodium sulfate. After the filtration, the crude product was obtained by removing the solvent. The residue was purified by flash column chromatography with n-hexane-ethylacetate(1:10) to give the desired product (1.5 g, 36%).

1H-NMR (CDCl3) δ 3.0 (m, 2H), 3.70 (t, 2H, J=7 Hz), 4.60 (s, 2H), 5.17 (s, 2H), 7.10-7.70 (m, 13H), 8.10 (d, 1H, J=8 Hz)

In the same procedure as in EXAMPLE 4, the compounds of EXAMPLE 5-8 were prepared and the results were as follows:

EXAMPLE R 1H-NMR:δ
5 CH2CH3 8.102(d, 1H, J=1.2Hz), 7.596-
7.315(m, 8H), 5.125(s, 2H),
3.762-3.61(m, 4H), 1.853(t, 2H,
J=6.4Hz), 1.159(t, 3H, J=7.2Hz)
6 CH2CH2CH3 8.124(d, 1H, J=1.2Hz), 7.700-
7.272(m, 8H), 5.125(s, 2H),
3.717(t, 2H, J=3.6Hz), 3.322-
3.279(m, 2H), 1.624-1.546(m, 4H)
0.894(t, 3H)
7 CH(CH3)2 8.115(d, 1H), 7.613-7.261(m, 8H)
5.135(s, 2H), 4.488-4.210(m, 1H)
3.639(t, 2H, J=7.2Hz), 1.260(t,
2H, J=7.2Hz), 1.165(d, 6H, J=6.4Hz)
8 CH2CH2OH 8.119(d, 1H, J=8.0Hz), 7.623-
7.261(m, 8H), 5.127(s, 2H),
3.802-3.719(m, 2H), 3.557(t, 2H,
J=5.2Hz), 3.392-3.353(m, 2H),
3.068-3.051(m, 2H)

EXAMPLE 9

Preparation of 3-(N-2′-acetoxyethyl-N-carbobenzyloxyamino)-1-(2′-nitrophenyl)propane-1-one

A mixture of 3-[(N-(2′-hydoxyethyl)-N-carbobenzyloxyamino )]-1-(2′-nitrophenyl)propane -1-one (40 mg, 0.107 mmol) and 4-dimethylamino pyridine (1.2 mg, 0.01 mmol) was dissolved in anhydrous dichloromethane(2 ml), then added triethylamine (0.02 ml, 0.160 mmol) and acetic anhydride(0.02 ml, 0.214 mmol). The reaction mixture was stirred at room temperature for 30 mins and washed with a saturated ammonium chloride aqueous solution, water and brine successively. Then, the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue, so obtained, was purified by column chromatography with ethylacetate-n-hexane (1:3) to give the desired product (40 mg, 90%) as a yellow oil.

1H-NMR (400 MHz, CDCl3) δ 8.123 (d, 1H, J=8.4 Hz), 7.607-7.261 (m, 8H), 5.136 (s, 2H), 4.194 (m, H), 3.784-3.754 (m, 2H), 3.660-3.646 (m, 2H), 3.172 (m; 2H), 2.047 (s, 3H)

EXAMPLE 10

Preparation of 3-morpholino-1-(2′-aminophenyl)propane-1-one

To a solution of 3-morpholino-1-(2′-nitrophenyl) propane-1-one(200 mg, 0.758 mmol) dissolved in 10 ml of 95% ethanol was added sodium dithionite(660 mg, 3.79 mmol) and the reaction mixture was stirred under reflux for 3 hrs. The reaction mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography with ethanol-dichloromethane-triethylamine to yield the desired product (174 mg, 89%) as an oil.

1H-NMR (CDCl3) δ 3.20 (m, 3H), 3.50 (m, 3H), 3.5 (m, 4H), 3.99 (m, 2H), 7.5-7.8 (m, 3H), 8.08 (d, 1H, J=8 Hz)

EXAMPLE 11

Preparation of 3-piperidino-1-(2′-aminophenyl) propane-1-one

The same procedure as in EXAMPLE 10 was applied to the compound of EXAMPLE 2 (200 mg, 0.758 mmol) and sodium dithionite(660 mg, 3.79 mmol) so that the desired product (174 mg, 89%) was yielded.

EXAMPLE 12 Preparation of 3-pyrrolidino-1-(2′-aminophenyl)propane-1-one

The same procedure as in EXAMPLE 10 was applied to the compound of EXAMPLE 3 (400 mg) and sodium dithionite (1.052 g, 6.05 mmol) so that the desired product (235 mg) was yielded.

In the same procedure as used in EXAMPLE 10, the compounds of EXAMPLE 13-17 were prepared and the results were as follows:

EXAM-
PLE R2 R1 1H-NMR:δ
13 CH2CH3 Cbz 7.365-7.262(m, 9H), 5.144(s, 2H),
3.764-3.71(m, 4H), 1.871-1.838(m,
2H), 1,253(t, 3H, J=7.2Hz)
14 CH2CH2CH3 Cbz 7.885-7.230(m, 9H), 5.142(s, 2H),
3.668-3.613(m, 2H), 3.265(t, 2H,
J=6.4Hz), 1.616-1.513(m, 4H),
0.895(t, 3H)
15 CH(CH3)2 Cbz 7.496(d, 1H, J=7.28Hz), 7.377-
7.349(m, 3H), 7.299-2.227(m, 5H)
5.172(s, 2H), 4.376-4.216(m, 1H),
3.534-3.371(m, 4H),
1.240-1.044(m, 6H)
16 CH2Ph Cbz 3.17(m, 2H), 3.65(m, 2H), 4.55(s,
2H), 5.10(s, 2H), 6.20(brs, NH2),
7.10-7.70(m, 13H), 8.10(d, 1H,
J=8Hz)
17 CH2CH2OAc Cbz 7.771(d, 1H, J=7.6Hz), 7.574-
7.262(m, 8H), 6.641(d, 2H, J=7.6
Hz), 5.114(s, 2H), 4.186(m, 2H)
3.773-3.169(m, 6H), 2.042(s, 3H)

EXAMPLE 18

Preparation of dl-7-[2-(N-benzyl-N-carbobenzyloxyamino)ethyl]camptothecin

A mixture of 3-(N-benzyl-N-carbobenzyloxyamino) -1-(2′-aminophenyl)propane-1-one(543 mg, 1.4 mmol) and 4-ethyl-6-oxo-1,4,7,8-tetrahydro-4-hydroxy-pyrano [3,4-f]indolizine-3,10(6H)-dione (263 mg, 1.0 mmol) was dissolved in toluene (50 ml). The reaction mixture was stirred under reflux for 30 mins, and ρ-toluenesulfonic acid (25 mg, 0.13 mmol) was added to the mixture. The reaction mixture was stirred in a Dean-Stark trap under reflux for 9 hrs. The solvent was removed under reduced pressure and the residue was purified by flash column chromatography with ethylacetate-dichloromethane (1:1) to give the desired product (507 mg, 59%) as a yellow powder.

1H-NMR (CDCl3) δ 1.04 (t, 3H, J=8 Hz), 1.90 (m, 2H), 3.10-3.90 (m, 4H), 4.53 (s, ½×2H), 4.61 (s, ½×2H), 4.95 (s, ½×2H), 5.07 (s, ½×2H), 5.30 (s, 2H), 5.31 (d, 1H, J=16 Hz), 5.75 (d, 1H, J=16 Hz), 7.20-8.20 (m, 15H)

In the same procedure as in EXAMPLE 18, the compounds of EXAMPLE 19 to 24 were prepared and the results were as follows:

EXAM-
PLE R2 R1 1H-NMR(CDCl3
19 CH2CH2CH3 Cbz 8.236-7.261(m, 10H), 5.757, 5.324
(ABq, 2H, J=16Hz), 5.293(s, 2H),
5.193(s, 2H), 3.593-3.199(m, 4H)
1.942-1.863(m, 2H), 1.634-1.516
(m, 4H), 1.047(t, 3H, J=7.2Hz),
0.944-0.842(m, 3H)
20 CH(CH3)2 Cbz 8.197(d, 1H), 7.926-7.628(m, 3H)
7.485-7.365(m, 6H), 5.694(d, 1H,
J=13.08Hz), 5.552-5.270(m, 3H)
5.246(s, 2H), 4.476-4.310(m, 1H),
3.514-3.456(m, 4H), 1.997-1.910
(m, 2H), 1.248-1,208(m, 6H),
1.044(t, 3H, J=5.92Hz)
21 CH2CH2OAc Cbz 8.344-7.261(m, 10H), 5.748(d, 1H
J=16.8Hz), 5.308(d, 1H, J=16.8Hz)
5.298(s, 2H), 5.113(s, 2H),
4.255-4.126(m, 2H), 3.791-3.371
(m, 6H), 2.041(s, 3H), 1.954-
1.610(m, 2H), 1.042(t, 3H, J=
7.2Hz)

EXAMPLE R1 R2 1H-NMR(CDCl)δ
22 piperidino 1H-NMR(200MHz, DMSO-d6) 0.92(t,
J=6Hz, 3H), 1.32(m, 6H), 1.90(m,
2H), 2.34(s, 3H), 2.90(m, 2H), 3.30
(m, 6H), 5.48(s, 2H), 5.49(s, 2H),
6.58(s, 1H), 7.16(d, J=8Hz, 2H),
7.52(d, J=8Hz, 2H), 7.77-8.30(m, 4H)
23 pyrrolidino 1H-NMR(200MHz, DMSO-d6)0.94(t, J=
6Hz, 3H), 1.25(m, 4H), 1.87(m, 2H),
2.33(s, 3H), 2.90(m, 2H), 3.11(m, 6H),
3.53(s, 1H), 5.52(s, 2H), 5.53(s,
2H), 6.60(s, 1H), 7.15(d, J=8Hz, 2H),
7.51(d, J=8Hz, 2H), 7.77-8.30(m, 4H)
24 morpholino 1H-NMR(200MHz, CDCl3)δ0.86(t, J=
6Hz, 3H), 1.89(m, 2H), 2.25(s, 3H)
2.85(m, 2H), 3.05(m, 2H), 3.51(m,
4H), 3.71(m, 4H), 5.39(s, 2H), 5.40
(s, 2H), 6.49(s, 1H), 7.08(d, J=8Hz,
2H), 7.44(d, J=8Hz, 2H),
7.70-8.30(m, 4H)

EXAMPLE 25

Preparation of dl-7-[2-(N-hydroxyethyl-N-carbobenzyloxyamino)ethyl]camptothecin

A mixture of dl-7-[2-(N-acetoxyethyl-N-carbobenzyloxyamino)ethyl]camptothecin (28.2 mg, 0.05 mmol) and potassium carbonate (25 mg, 0.15 mmol) was dissolved in mixed a solution of methanol and water (1:1, 1.5 ml) and the reaction mixture solution was stirred at room temperature for 3 hrs. The reaction mixture was acidified with 1N HCl solution, extracted with dichloromethane and washed with brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography with dichloromethane-methanol (20:1) to give the desired product (17 mg, 60%) as a yellow solid.

1H-NMR (400 MHz, CDCl3) δ 8.171-7.762 (m, 10H), 5.710 (d, 2H, J=16.8 Hz), 5.308 (d, 2H, J=16.8 Hz), 5.301 (s, 2H), 5.207 (s, 2H), 3.868-3.466 (m, 8H), 1.926-1.832 (m, 2H), 1.033 (t, 3H, J=7.6 Hz)

EXAMPLE 26 Preparation of dl-7-[2-(N-benzylamino) ethyl]camptothecin

dl-7-[2-(N-Benzyl-N-carbobenzyloxyamino)ethyl]camptothecin (50 mg, 0.08 mmol) was dissolved in glacial acetic acid (20 ml) and treated with 10% Pd/C (25 mg). The reaction mixture was stirred under hydrogen flow of 40 psi for 9 hrs, and the catalyst was removed through cellite pad by filtration under reduced pressure. The filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography with 10% methanol-dichloromethane to give the desired product (24 mg, 63%) as a yellow powder.

1H-NMR (400 MHz, CDCl3) δ 0.89 (t, 3H, J=8 Hz), 1.87 (m, 2H), 2.90 (m, 2H), 3.5 (m, 4H), 3.73 (s, 1H), 5.33 (s, 2H), 5.43 (s, 2H), 6.52 (s, 1H), 7.25 (m, 6H), 7.70-8.30 (m, 4H)

EXAMPLE 27

Preparation of dl-7-[2-(N-acetoxyethylamino) ethyl]camptothecin

The same procedure as in EXAMPLE 26, was carried out.

1H-NMR (400 MHz, CDCl3+MeOH-d4) δ 8.323 (d, 1H, J=8.8 Hz), 8.138 (d, 1H, J=8.4 Hz), 7.812 (t, 1H, J=6.8 Hz), 7.675 (t, 1H, J=6.8 Hz), 7.647 (s, 1H), 5.742 (d, 1H J=16.4 Hz), 5.324-5.284 (m, 2H), 4.169-4.122 (m, 2H), 3.373 (t, 2H, J=7.6 Hz), 3.108-3.040 (m, 4H), 2.090 (s, 3H), 2.024 (s, 3H), 1.955-1.803 (m, 2H), 1.033 (t, 3H, J=7.6 Hz)

EXAMPLE 28

Preparation of dl-7-[2-(N-hydroxyethyl amino)ethyl]camptothecin

The same procedure as in EXAMPLE 26, was carried out.

1H-NMR (CDCl3+MeOH-d4) 8.284 (d, 1H, J=8.0 Hz), 8.226 (d, 1H, J=8.8 Hz), 7.863 (t, 1H, J=6.8 Hz), 7.756 (t, 1H, J=6.8 Hz), 7.730 (s, 1H), 5.682 (d, 1H,J=13.6 Hz), 5.641 (d, 1H, J=13.6 Hz), 5.130 (s, 2H), 3.800-3.190 (m, 8H), 1.962-1.898 (m, 2H), 1.031 (t, 3H, J=4.4 Hz), 2.035 (s, 3H)

EXAMPLE 29

Preparation of dl-7-[2-(N-ethylamino)ethyl]camptothecin

A mixture of 2′-amino-2-(N-carbobenzyloxy-N-ethylamino)propiophenone (34 mg, 0.11 mmol) and 4-ethyl-6-oxo-1,4,7,8-tetrahydro-4-hydroxy-pyrano[3, 4-f]indolizine-3,10(6H)-dione(34 mg, 0.1 mmol) was dissolved in toluene and was refluxed for 30 mins. After addition of ρ-toluenesulfonic acid (19.2 mg, 0.11 mmol), the reaction mixture was then refluxed in a Dean-Stark trap for 3 hrs. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography with dichloromethane-methanol (10:1) to give the desired product(40 mg, 67%) as a solid.

1H-NMR (400 MHz, DMSO-d6) δ 8.280 (d, 1H, J=8.6 Hz), 8.184 (d, 1H, J=7.4 Hz), 7.873-7.753 (m, 2H), 7.471 (d, 2H, J=7.2 Hz), 7.111 (d, 2H, J=7.2 Hz), 7.356 (s, 1H), 6.523 (s, 1H), 5.439 (s, 2H), 3.534-2.753 (m, 6H), 2.217 (s, 3H), 1.671-1.643 (m, 2H), 1.230 (t, 3H, J=6.8 Hz), 0.743 (t, 3H,J=7.2 Hz)

EXAMPLE 30

Preparation of dl-7-[2-(N-isopropylamino)ethyl]camptothecin

The same procedure as in EXAMPLE 29 was carried out.

1H-NMR (400 MHz, DMSO-d6) δ 8.870-8.567 (m, 2H), 8.298-8.155 (m, 2H), 7.867 (d, 2H, J=7.6 Hz), 7.741 (s, 1H), 7.500 (d, 2H, J=7.6 Hz), 5.828 (s, 2H), 5.795 (s, 2H), 3.958-3.820 (m, 2H), 2.666 (s, 3H), 2.320-2.200 (in, 2H), 1.614 (d, 6H, J=6.4 Hz), 1.533 (t, 2H), 1.267 (t, 3H)

EXAMPLE 31

dl-7-[2-(Morpholino)ethyl]camptothecin trifluoro-acetate

The same procedure as in EXAMPLE 24 was carried out except that trifluoroacetic acid was used instead of p-toluenesulfonic acid.

1H-NMR (200 MHz, DMSO-d6) δ 0.92 (t, J=6 Hz, 3H), 1.94 (m, 2H), 2.90 (m, 4H), 3.30-3.65 (m, 8H), 5.47 (s, 2H), 5.48 (s, 2H), 6.56 (s, 1H), 7.70-8.30 (m, 4H)

EXAMPLE 32

Preparation of 6-cyano-1,1-(ethylenedioxy) -7-[1′-(ethoxycarbonyl)-3′-(methoxymethyloxypropyl]-5-oxo-Δ6(8)-tetrahydroindolizine

6-Cyano-1,1-(ethylenedioxy)-7-[(ethoxycarbonyl)methyl]-5-oxo-Δ6(8)-tetrahydroindolizine (608.6 mg, 2 mmol) was dissolved in anhydrous dimethylformamide (3 ml), cooled to 5° C. and after addition of potassium t-butoxide (258.1 mg, 2.3 mmol), the reaction mixture was stirred at the same temperature for 30 mins. To this mixture, 2-brmoethanolmethoxy-methylether (1.352 g, 8 mmol) was added and the reaction mixture was stirred at 45-50° C. for 20 hrs. The reaction mixture was diluted with water(50 ml), extracted with dichloromethane (100 ml). The organic layer was washed with water(80 ml) and brine(80 ml), dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography with ethylacetate-n-hexane (2:1) to give the desired product (734.8 mg, 95%) as a pale yellow solid.

IR(neat) 2224, 1734, 1656 cm−1

1H-NMR (400 MHz, CDCl3) δ 1.254 (t, 3H, J=6.8 Hz), 1.987-2.020 (m, 1H), 2.410 (t, 2H, J=6.8 Hz), 2.43-2.449 (m, 1H), 3.447-3.485 (m, 1H) 3.564-3.603 (m, 1H), 4.117-4.201 (m, 7H), 4.225 (q, 2H J=7.6 Hz),4.584, 4.609 (ABq, 2H, J=6.8 Hz),6.367 (s, 1H)

MS(EI) m/e 392 (M+), 377 (M+−CH3), 361 (M+−OCH3), 347 (M+−C2H5O)

EXAMPLE 33

Preparation of 6-(acetamidomethyl)-1,1-(ethylenedioxy)-7-[1′-(ethoxycarbonyl)-3° C.-(methoxymethyl oxypropyl)]-5-oxo-Δ6(8)-tetrahydroindolizine

250 Drops of Raney-Nickel (50% aqueous slurry) was washed with water (5 ml) and acetic acid (10 ml) 5 times respectively and added into a parr bottle.

To this solution, a compound(743.8 mg, 1.9 mmol), obtained in EXAMPLE 32, acetic anhydride(30 ml) and acetic acid (10 ml) were added and the reaction mixture was hydrogenated at a pressure of 45 psi and 45-50° C. for 3 hrs. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with dichloromethane-methanol (20:1) to give the desired product(789.5 mg, 95%) as a yellow oil.

IR(neat) 1733, 1660, 1635 cm−1

1H-NMR (400 MHz, CDCl3) δ 1.214 (t, 3H, J=6.8 Hz), 1.924 (s, 3H), 1.939-1.98 (m, 1H), 2.382 (t, 2H, J=6.8 Hz), 2.399-2.40 (m, 1H), 3.343 (s, 3H), 3.44-3.58 (m, 2H), 4.075-4.131 (m, 7H), 4.145 (q, 2H), 4.34, 4.39 (d, d, 2H), 4.571, 4.592 (ABq, 2H, J=6.8 Hz), 6.306 (s, 1H), 6.61 (brs, 1H)

MS(EI) m/e 438 (M+), 423 (M+−CH3), 407 (M+−OCH3), 395 (M+−COCH3), 393 (M′—C2H5O)

EXAMPLE 34

Preparation of 6-(acetoxymethyl)-1,1-(ethylenedioxy)-7-[1′-(ethoxycarbonyl)-3′-(methoxymethyloxypropyl)]-5-oxo-Δ6(8)-tetrahydroindolizine

To a compound (789.5 mg, 1.8 mmol) obtained in EXAMPLE 33, acetic anhydride(15 ml), acetic acid(5 ml) and sodium nitrite(621.2 mg, 9 mmol) were added and the reaction mixture was stirred at 5 to 10° C. for 6 hrs. After removing the inorganic material, so formed by filtration, the filtrate was concentrated under reduced pressure to give nitroso compound. With addition of carbon tetrachlonride (50 ml), the mixture was heated under reflux for 18 hrs. The reaction mixture was washed with water (10 ml) and brine (10 ml), dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography. with dichloromethane -methanol(20:1) to give the desired product (720 mg, 91%) as a colorless oil.

IR(neat) 1740, 1733, 1654 cm−1

1H-NMR (400MHZ, CDCl3) δ 1.217 (t, 3H, J=6.8 Hz), 1.86-1.95 (m, 1H), 2.056 (s, 3H), 2.368 (t, 2H), 2.38-2.43 (m, 1H), 3.333 (s, 3H), 3.41-3.57 (m, 2H), 4.087-4.119 (m, 9H), 4.569 (s, 2H), 5.259 (s, 2H), 6.304 (s, 1H)

MS(EI) m/e 439 (M+), 408 (M+−OCH3), 396 (M+−COCH3)

EXAMPLE 35

Preparation of 1,1-(ethylenedioxy)-(5′-methoxymethyloxyethyl-2′H,5′H,6′H-6-oxopyrano) [3′,4′-f]-5-oxo-Δ6(8)-tetrahydroindolizine

A mixture of the compound (720 mg, 1.64 mmol) obtained in prepared by EXAMPLE 34 and methanol (15 ml) was added to LiOH.H2O (172 mg, 4.1 mmol) dissolved in water (5 ml) and stirred at 25 to 30° C. for 2 hrs. The reaction mixture was concentrated under reduced pressure to remove methanol and with addition of water(15 ml), dichloromethane(50 ml) and acetic acid (5 ml), the reaction mixture was stirred at 25 to 30° C. for 10 hrs. The organic layer was separated from the reaction mixture, washed with water (10 ml) and brine (10 ml) and dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure. The residue was purified by column chromatography with dichloromethanemethanol (30:1) to give the desired product (720 mg, 91%) as a white solid.

IR(neat) 1747, 1662 cm−1

1H-NMR (400 MHz, CDCl3) δ 2.178-2.216 (m, 2H), 2.404 (t, 2H, J=6.8 Hz), 3.371 (s, 3H), 3.599-3.643 (m, 2H), 3.701 (t, 1H, J=6.8 Hz), 4.109-4.192 (m, 6H), 4.618 (s, 2H), 5.278, 5.43 (ABq, 2H, J=16.4 Hz), 6.169 (s, 1H)

MS(EI) m/e 351 (M+), 320 (M+−OCH3), 307 (M+−CO2)

EXAMPLE 36

Preparation of 1,1-(ethylenedioxy)-(5′-methoxymethyloxyethyl-5′-hydroxy-2′H,5′H,6′H-6-oxopyrano)[3′,4′-f]-5-oxo-Δ6(8)-tetrahydroindolizine

Potassium t-butoxide (273 mg, 2.43 mmol) was added to a mixture of the compound (570.3 mg, 1.63 mmol) obtained in EXAMPLE 35 dissolved in anhydrous DMF (20 ml) and stirred at 0 to 5° C. for 30 mins. The reaction mixture was cooled to −10 to −5° C. and with addition of triethyl phosphite (974 μl, 5.68 mmol), the mixture was stirred for 2.5 hrs, while bubbling the oxygen. Water (10 ml) was added to the mixture and pH was adjusted to 3.5 with 1N-HCl. Then, the reaction mixture was extracted with dichloromethane (30 ml×2 times), washed with water (20 ml), and brine (20 ml) and dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure. The residue was purified by column chromatography with dichloromethane-methanol (25:1) to give the desired product (416.4 mg, 69.8%) as a white solid.

IR(neat) 3503, 1749, 1654 cm−1

1H-NMR (400 MHz, CDCl3) δ 1.919-1.974 (m, 1H), 2.010-2.063 (m, 1H), 2.348 (t, 2H, J=6.8 Hz), 3.30 (s, 3H), 3.542-3.597 (m, 1H), 3.639-3.684 (m, 1H), 4.002-4.1541 (m, 7H), 4.516, 4.494 (ABq, 2H, J=6.4 Hz), 5.111, 5.557 (ABq, 2H, J=16 Hz), 6.541 (s, 1H)

MS(EI) m/e 367 (M+), 336 (M+−OCH3), 323 (M+−CO2)

EXAMPLE 37 :

Preparation of 1,5-dioxo-(5′-hydroxyethyl-5′-hydroxy-2′H,5′H,6/H-6-oxopyrano)[3′,4′-f]-Δ6(8)-tetrahydroindolizine

A mixture of THF (200 ml), water (1 ml) and 6N HCl (2.5 ml) was added to the compound (146.1 mg, 0.4 mmol) obtained in EXAMPLE 36 and stirred at 50-55° C. for 1 hr. The reaction mixture was concentrated under reduced pressure. The residue was purified by DianionR HP-20 (Mitsubishi) with acetonitrile-water (4:1) and concentrated under reduced pressure to give the desired product (93.2 mg, 84%) as a black resin.

IR(KBr) 3470, 1749, 1654 cm−1

1H-NMR (400 MHz, CDCl3) δ 1.92-2.11 (m, 2H), 2.962 (t, 2H, J=6.0 Hz), 3.674-3.86 (m, 2H), 4.326 (t, 2H, J=6.0 Hz), 5.259, 5.627 (ABq, 2H, J=16.8 Hz), 5.287 (s, 1H), 7.284 (s, 1H)

MS(EI) m/e 279 (M+), 261 (M+−H2O), 235 (M+−C2H5OH)

EXAMPLE 38

Preparation of dl-18-hydroxycamptothecin

A solution of 2-aminobenzaldehyde ethyleneacetal (75.6 mg, 0.46 mmol) and toluene (8 ml) was added to the compound (85.2 mg, 0.31 mmol) obtained in EXAMPLE 37 and refluxed in a Dean-Stark apparatus for 1 hr. p-toluene-sulfonic acid (catalytic amount) was added to the reaction mixture and refluxed again for 3 hrs. The solid, so formed, was filtered and purified by column chromatography with dichloromethane-methanol (15:1) to give the desired product (57.8 mg, 52%) as a pale brown solid.

IR(neat) 3400, 1743, 1658 cm−1

1H-NMR (400 MHz, CDCl3:DMSO-d6=3:1) δ 2.01-2.20 (m, 2H), 3.51-3.86 (m, 2H), 5.315 (s, 2H), 5.34, 5.55 (ABq, 2H), 6.418 (s, 1H), 7.557 (s, 1H), 7.676 (t, 1H), 7.83 (t, 1H), 8.03 (d, 1H), 8.18 (d, 1H), 8.570 (s, 1H)

MS(EI) m/e 364 (M+), 320 (M+−CO2)

EXAMPLE 39

Preparation of dl-18-methoxymethyloxy camptothecin

Methoxymethyl chloride (6 μl, 0.08 mmol) and diisopropylethylamine (12 μl, 0.07 mmol) was added to a suspension of dl-18-hydroxycamptothecin (20 mg, 0.05 mmol) in dichloromethane (2 ml) and stirred at 25 to 30° C. for 48 hrs.

With addition of dichloromethane (25 ml), the reaction mixture was washed with a saturated ammonium chloride (10 ml), water (10 ml), 10% hydrogen sulfate potassium (10 ml), water (10 ml) and brine (10 ml) successively. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography with dichloromethane-methanol (30:1) and PTLC with dichloromethane-methanol (20:1) to give the desired product (5 mg, 23%) as a yellow solid.

IR (KBr) 3566, 1733, 1652 cm−1

1H-NMR (400 MHz, CDCl3) δ 2.15-2.34 (m, 2H), 3.387 (s, 3H), 4.08-4.22 (m, 2H), 4.604 (d, d, 2H), 5.313 (s, 2H), 5.62, 5.78 (ABq, 2H), 6.6 (s, 1H), 7.68 (t, 1H), 7.726 (s, 1H), 7.84 (t, 1H), 7.96 (d, 1H), 8.24 (d, 1H), 8.41 (s, 1H)

MS(EI) m/e 408 (M+) HRMS m/e M+Calcd; 408.1321, Obsd; 408.1336

In the same manner as in EXAMPLE 39, the compounds (R=H and n=2) of EXAMPLE 40 to 46, expressed by the general formula (I), were prepared.

EXAM-
PLE R3 1H-NMR (CDCl3 or CDCl3 + CD3OD) δ
40 OCOCH3 1.970(s, 3H), 2.26-2.37(m, 2H), 4.126-
4.216(m, 2H), 5.32(s, 2H), 5.66,
5.79 (Aq, 2H), 6.36(s, 1H), 7.65(s,
1H), 7.69(t, 1H), 7.86(t, 1H), 7.95
(d, 1H), 8.25(d, 1H), 8.41(s, 1H)
41 OCOCH2OCH3 8.3975(s, 1H), 8.2429(d, 1H, J=8.5Hz)
7.9401(d, 1H, J=8.3Hz), 7.8358(t, 1H),
7.6936(s, 1H), 7.6845(t, 1H), 5.7928
5.3225(ABq, 2H, J=16.2Hz), 5.3064(s,
2H), 4,2762-4.2991(m, 1H), 4.18-4.22
(m, 1H), 3.9794(d, 2H, J=2.4Hz),
3.4106(s, 3H), 2.2333-2.2444(m, 2H)
42 OCH2OCH2CH3 8.4035(s, 1H), 8.2411(d, 1H, J=8.4Hz)
7.945(d, 1H, J=7.4Hz), 7.8409(t, 1H,
J=7.0Hz), 7.7274(s, 1H), 7.6744(t, 1H
J=7.0Hz), 5.7673, 5.3189(ABq, 2H, J=
16.2Hz), 5.3132(s, 2H), 4.6547(ABq,
2H), 4.3373(s, 1H), 4.2345(q, 2H),
3.81(m, 1H), 3.7144(m, 1H), 2.22(m,
1H), 2.11(m, 1H), 1.2186(t, 3H)
43 OCH2OCH2CH2OCH3 8.4018(s, 1H), 8.2391(d, 1H, J=8.4Hz),
7.9423(d, 1H, J=7.6Hz), 7.8388(t, 1H),
7.7236(s, 1H), 7.6925(t, 1H), 5.7629,
5.3223(ABq, 2H, J=16.3Hz), 5.3111(s,
2H), 4.6934(d, d, 2H), 3.8514(m, 1H)
3.7011-3.7435(m, 2H), 3.65(m, 1H),
3.5602-3.5828(m, 2H), 3.3976(s, 3H),
2.01-2.22(m, 2H)
44 OCONHPh 2.074-2.188(m, 1H), 2.308-2.361(m, 1H),
4.122-4.163(m, 1H), 4.279-4.303(m, 1H)
5.153, 5.263(ABq, 2H, J=19.2Hz)
5.464 (s, 2H), 6.707(t, 1H, J=7.2Hz)
7.013(t, 2H, J=8.0Hz), 7.202(d, 2H,
J=8.0Hz), 7.350(s, 1H), 7.693(t, 1H
J=7.2Hz), 7.842(t, 1H, J=8.4Hz),
8.086(d, 1H, J=8.4Hz), 8.122(d, 1H,
J=8.0Hz), 8.611(s, 1H), 9.337(brs, 1H)
45 OCONHCH2CH2—Cl 9.19(brs, 1H), 8.3989(s, 1H), 8.2469
(d, 1H, J=8.4Hz), 7.9399(d, 1H, J=7.9
Hz), 7.8384(t, 1H), 7.7171(s, 1H),
7.6727(t, 1H), 5.7667, 5.3430(ABq,
2H), 5.2748(q, 2H), 3.8914(m, 1H),
3.78(m, 1H), 3.5472-3.5995(m, 2H),
3.4507-3.4833(m, 2H), 2.22(m, 2H)
46 OCONH i-Pr. 8.3909(s, 1H), 8.2033(d, 1H, J=8.7Hz)
7.9206(d, 1H, J=7.5Hz), 7.8150(t, 1H)
7.7022(s, 1H), 7.6551(t 1H), 5.7112,
5.2815(ABq, 2H, J=16.2Hz), 5.2778(s,
2H), 4.2720(m, 1H), 4.1706-4.1982(m,
1H), 3.6538(m, 1H), 2.2597(m, 2H),
1.1270(d, 6H)

EXAMPLE 47

Preparation of 6-cyano-1,1-(ethylenedioxy)-7-[1′-(ethoxycarbonyl)-2′-hydroxyethyl]-5-oxo-Δ6(8)-tetrahydroindolizine

A mixture of 35% formaldehyde (30 ml), dioxane (50 ml), water (20 ml) and ethanol (20 ml) was added to 6-cyano-1,1-(ethylenedioxy)-7-[(ethoxycarbonyl)methyl]-5-oxo-Δ6(8)-tetrahydroindolizine (500 mg, 1.64 mmol) and stirred at 25 to 30° C. for 15 hrs. With addition of dichloromethane (120 ml), the reaction mixture was washed with water(120 ml×3 times) and brine (120 ml). The separated organic layer was dried over anhydrous magnesum sulfate and concentrated under reduced pressure. The residue was purified by column chromatography with dichloromethane-methanol (25:1) to give the desired product (318 mg, 58%) as a white solid.

IR (KBr) 3310, 2224, 1735, 1647 cm−1

1H-NMR (400 MHz, CDCl3) δ 1.275 (t, 3H, J=7.2 Hz), 2.407 (t, 2H, J=6.8 Hz), 4.029-4.221 (,m, 9H), 4.239 (q, 2H), 6.383 (s, 1H)

MS(EI) m/e 334 (M+), 316 (M+−H2O), 304 (M+−CH3OH)

EXAMPLE 48

Preparation of 6-cyano-1,1-(ethylenedioxy)-7-[1′-(ethoxycarbonyl)-2′-(methoxyethoxymethyloxyethyl)]-5-oxo-Δ6(8)-tetrahydroindolizine

Dichloromethane(0.7 ml) was added to the compound(51.6 mg, 0.15 mmol) obtained in EXAMPLE 47 and cooled in ice bath. Then, with a slow addition of diisopropylethylamine (30 μl, 0.17 mmol) and MEM-Cl (35 μl, 0.31 mmol), the resulting solution was stirred at 25 to 30° C. for 20 hrs. To the reaction mixture, dichloromethane (15 ml) was added and washed with a saturated sodium bicarbonate aqueous solution (10 ml×2 times), water (10 ml) and brine (10 ml). The separated organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography with dichloromethane-methanol (25:1) to give the desired product (41 mg, 62%) as a white solid.

IR(neat) 2224, 1734, 1661 cm−1

1H-NMR (400 MHz, CDCl3) δ 1.289 (t, 3H, J=6.8 Hz), 2.422 (t, 2H, J=6.8 Hz), 3.410 (s, 3H), 3.548-3.598 (m, 2H), 3.653-3.680 (m, 1H), 3.725-3.748 (m, 1H), 3.912 (dd, 1H, J=10 Hz, J=6.8 Hz), 4.098 (dd, 1H, J=10 Hz, J=6.8 Hz), 4.129-4.216 (m, 6H), 4.236 (q, 2H), 4.336 (t, 1H, J=6.8 Hz), 4.706, 4.742 (ABq, 2H, J=6.8 Hz), 6.441 (s, 1H)

MS(EI) m/e 423 (M++H), 422 (M+), 392 (M+−OCH3), 378 (M+−C2H5O)

EXAMPLE 49

Preparation of 6-(acetamidomethyl)-1,1-(ethylenedioxy)-7-[1′-(ethoxycarbonyl)-2′-(methoxyethoxymethyloxyethyl)]-5-oxo-Δ6(8)-tetrahydroindolizine

With the compound(39.6 mg, 0.09 mmol) obtained in EXAMPLE 48, the reaction and work-up was carried out in the same procedure as in EXAMPLE 33 and then, the residue was purified by column chromatography with dichloromethane-methanol (20:1) to give the desired compound(42 mg, 96%) as a colorless oil.

IR(neat) 1733, 1661, 1656 cm−1

1H-NMR (400 MHz, CDCl3) δ 1.247 (t, 3H, J=7.2 Hz), 1.943 (s, 3H), 2.393 (t, 2H, J=6.8 Hz), 3.405 (s, 3H), 3.546-3.569 (m, 2H), 3.660 -3.686 (m, 2H), 3.809 (dd, 1H, J=6.4 Hz, J=9.2 Hz), 4.093-4.192 (m, 7H), 4.205 (g, 2H), 4.467 (dq, 2H, J=6.4 Hz), 4.652 (t, 2H, J=6.8 Hz), 4.719, 4.750 (ABq, 2H, J=6.8 Hz), 6.349 (s, 1H), 6.658 (s, 1H)

MS(EI) m/e 468 (M+), 453 (M+−CH3), 425 (M+−C2H5O)

EXAMPLE 50

Preparation of 6-(acetoxymethyl)-1,1-(ethylenedioxy)-7-[1′-(ethoxycarbonyl)-2′-(methoxyethoxymethyloxyethyl)]-5-oxo-Δ6(8)-tetrahydroindolizine

With the compound (359 mg, 0.76 mmol) obtained in EXAMPLE 49, the reaction and work-up was carried out in the same procedure as used in EXAMPLE 34 and then, the residue was purified by column chromatography with dichloromethane methanol (30:1) to give the desired compound(234 mg, 65%) as a colorless oil.

IR(neat) 1733, 1740, 1661 cm−1

1H-NMR (400 MHz, CDCl3) δ 1.230 (t, 2H, J=7.2 Hz), 2.057 (s, 3H), 2.361 (t, 2H, J=6.8 Hz), 3.381 (s, 3H), 3.521-3.542 (m, 2H), 3.620-3.653 (m, 2H), 3.723 (dd, 1H, J=6.0 Hz, J=9.6 Hz), 4.082-4.209 (m, 8H), 4.225 (5, 2H), 4.716-4.675 (ABq, 2H, J=6.8 Hz), 5.259 (s, 2H), 6.313 (s, 1H)

MS(EI) m/e 469 (M+), 426 (M+−COCH3)

EXAMPLE 51

Preparation of 6-(acetoxymethyl)-1,1-(ethylenedioxy)-7-[1′-(ethoxycarbonyl)vinyl]-5-oxo-Δ6(8)-tetrahydroindolizine

A mixture of dry benzene (8 ml) and DBU (416 μl, 2.78 mmol) was added to the compound(522 mg, 1.1 mmol) obtained in EXAMPLE 50 and stirred at room temperature for 3 hrs. With addition of dichloromethane (20 ml), the reaction mixture was washed with a saturated ammonium chloride aqueous solution (15 ml×2) and water (15 ml). The separated organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography with dichloromethane-methanol (30:1) to give the desired product (363 mg, 90%) as a yellowish white solid.

IR(neat) 1729, 1719, 1655 cm−1

1H-NMR (400 MHz, CDCl3) δ 6.551 (s, 1H), 6.109, 5.773 (s, s, 1H×2), 5.008 (s, 2H), 4.243 (q, 2H, J=7.2 Hz), 4.104-4.161 (m, 6H), 2.398 (t, 2H, J=6.8 Hz), 2.021 (s, 3H), 1.293 (t, 3H, J=7.2 Hz)

MS(EI) m/e 363 (M+), 320

EXAMPLE 52

Preparation of 6-(acetoxymethyl) -1,1-(ethylenedioxy)-7-[1′-(ethoxycarbonyl)-1′-(hydroxy)-2′-(hydroxy)ethyl]-5-oxo-Δ6(8)-tetrahydroindolizine

Pyridine (3.9 ml) was added to the compound(285 mg, 1.79 mmol) obtained in EXAMPLE 51, injected with OsO4 (240 mg, 0.94 mmol)(0.08M toluene, 11.8 ml) and stirred at room temperature for 4 hrs in the dark. After the reaction was completed, the reaction mixture was added with a solution of NaHSO3 (480 mg) and water (7 ml) and stirred for 1 hr. The reaction mixture was extracted with dichloromethane (30 ml×5), and the combined organic layers were washed with brine and dried over anhydrous magnesium sulfate.

The organic layer was concentrated under reduced pressure. The residue was purified by column chromatography with dichloromethane-methanol (20:1) to give the desired product (280 mg, 90%) as a white solid.

IR(neat) 3307, 1735, 1654 cm−1

1H-NMR (400 MHz, CDCl3) δ 6.455 (s, 1H), 5.303 (ABq, 2H, J=11. 7 Hz), 4.611 (s, 1H) 4.085-4.611 (m, 9H), 3.855, 3.826 (dd, 1H, J=6.8, 11.2 Hz), 2.641 (brt, 1H, J=6.8 Hz), 2.384 (t, 2H, J=6.8 Hz), 2.063 (s, 3H), 1.290 (t, 3H, J=6.8 Hz)

MS(EI) m/e 397 (M+), 354

EXAMPLE 53

Preparation of 1,1-(ethylenedioxy)-(5′-hydroxy methyl-5′-hydroxy-2′H,5′H,6′H-6-oxopyrano)[3′,4′-f]-5-oxo-Δ6(8)-tetrahydroindolizine

With the compound(325 mg, 0.82 mmol) obtained in EXAMPLE 52, the reaction and work-up was carried out in the same procedure as in EXAMPLE 35 and then, the residue was purified by column chromatography with dichloromethane-methanol (20:1) to give the desired compound (211 mg, 84%) as a white solid.

IR(neat) 3421, 1750, 1654 cm−1

1H-NMR (400 MHz, CDCl3) δ 6.599 (s, 1H), 5.564, 5.255 (ABq, 2H, J=16.0 Hz), 4.072-4.238 (m, 7H), 3.772, 3.733 (dd, 2H, J=11.6 Hz), 2.418 (t, 2H, J=6.8 Hz)

MS(EI) m/e 309 (M+), 293, 280, 279, 265

HRMS m/e (M+) Calcd: 309, 0849, Obsd: 309, 0.847

EXAMPLE 54

Preparation of 1,1-(ethylenedioxy)-(5′-acetoxymethyl-5′-hydroxy-2′H,5′H,6′H-6-oxopyrano)[3′,4′-f]-5-oxo-Δ6(8)-tetrahydroindolizine

The compound (119 mg, 0.38 mmol) obtained in EXAMPLE 53 was dissolved in anhydrous dichloromethane (10 ml) and with addition of pyridine (93 μl, 1.15 mmol) and acetic anhydride (47 μl, 0.50 mmol), the reaction mixture was stirred at room temperature for 20 hrs. The reaction mixture was diluted with dichloromethane (20 ml), washed with 10% potassium bisulfate aqueous solution (20 ml), water (20 ml) and brine (20 ml), and dried over anhydrous magnesium sulfate.

The organic layer was concentrated under reduced pressure. The residue was purified by column chromatography with dichloromethane-methane (20:1) to give the desired compound (127 mg, 94%) as a white solid.

IR(neat) 3437, 1751, 1657 cm−1

1H-NMR (400 MHz, CDCl3) δ 6.586 (s, 1H), 5.636, 5.295 (ABq, 2H, J=16.4 Hz), 4.302 (d, 1H, J=11.2 Hz), 4.116-4.215 (m, 7H), 4.004 (s, 1H), 2.427 (t, 2H, J=6.8 Hz), 2.084 (s, 3H)

In the same procedure as used in EXAMPLE 54, the compounds of EXAMPLE 55 to 57 were prepared and the results were as follows:

EXAMPLE R3 1H-NMR(CDCl3
55 OCONHPh 8.205(brs, 1H), 7.260-7.436(m, 4H),
7.055(d, 1H), 6.661(s, 1H), 5.587,
5.357(ABq, 2H), 4.366, 4.319(d, d,
2H, J=11.2Hz), 4.101-4.227(m, 6H),
2.413(t, 2H, J=6.8Hz)
56 OCONH i-Pr. 6.61(s, 1H), 5.64, 5.56(ABq, 2H),
4.66(d, 1H), 4.53(d, 1H), 4.1253(m,
6H), 3.7981-3.8826(m, 1H), 2.4203(t,
2H), 1.1478(d, 6H)
57 6.5831(s, 1H), 5.6356, 5.3385(ABq, 2H, J=16.4Hz), 4.3821(d, 1H, J=11.4 Hz), 4.2693(d, 1H, J=11.4Hz), 4.1275-4.2176(m, 6H), 4.0542(d, 2H, J=2.0Hz), 3.4240(s, 3H), 2.4235(t, 2H, J=6.8Hz)

EXAMPLE 58

Preparation of 1,5-dioxo-(5′-acetoxymethyl-5′-hydroxy-2′H,5′H,6′H-6-oxopyrano)[3′,4′-f]-Δ6(8)-tetrahydroindolizine

80% trifluoroacetic acid(1.3 ml) was added to the compound (127 mg, 0.36 mmol) obtained in EXAMPLE 54 and stirred at room temperature for 2 hrs. The reaction mixture was concentrated under reduced pressure and with addition of brine, the reaction mixture was extracted with dichloromethane (20 ml×3) and dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure. The residue was purified by column chromatography with dichloromethane-methanol (20:1) to give desired product (theoretical yield) as a yellow solid.

IR (KBr) 3412, 1746, 1660 cm−1

1H-NMR (400 MHz, CDCl3) δ 7.318 (s, 1H), 5.687, 5.388 (ABq, 2H, J=17.1 Hz), 4.405 (t, 2H), 4.370 (d, 1H, J=11.7 Hz), 4.155 (d, 1H, J=11.7 Hz), 3.007 (t, 2H, J=6.8 Hz), 2.080 (s, 3H)

MS(EI) m/e 307 (M+)

In the same manner as used in EXAMPLE 58, the compounds (n=1) of EXAMPLE 59 to 61, expressed by the general formula (III),were prepared from the compounds of Examples 55, 56, and 57, respectively.

EXAMPLE R3 1H-NMRδ
59 OCONHPh 8.646(brs, 1H), 7.339(s, 1H), 7.156-
7.356(m, 5H), 6.092(s, 1H), 5.573,
5.31(ABq, 2H), 4.359, 4.318(d, d, 2H)
4.267(t, 2H), 2.885(t, 2H)
60 OCONH i-Pr. 7.2509(s, 1H), 5.65, 5.3550(ABq, 2H,
J=17.2Hz), 4.71(d, 1H), 4.52(d, 1H),
4.3554(t, 2H, J=6.8Hz), 3.7965-3.8806
(m, 1H), 2.9616(t, 2H, J=6.8Hz),
1.1335.(d, 6H)
61 used immediately to the next reaction without further purification

EXAMPLE 62

Preparation of dl-20-desethyl-20-acetoxymethyl camptothecin

With the compound(19 mg, 0.06 mmol) obtained from EXAMPLE 58 and N-(2-aminobenzylidene)-p-toluidine (20 mg, 0.09 mmol), the reaction and work-up was carried out in the same procedure as in EXAMPLE 38 and then, the residue was purified by PTLC with dichloromethane-methanol (20:1) to give the desired compound(9 mg, 36%) as a brown solid.

IR(CHCl3) 3400, 1749, 1740, 1654 cm−1

1H-NMR (400 MHz, CDCl3+CD3OD=4:1) 8.493 (s, 1H), 8.223 (d, 1H, J=8.4 Hz), 7.988 (d, 1H, J=8.0 Hz), 7.867 (t, 1H, J=7.2 Hz), 7.767 (s, 1H), 7.703 (t, 1H, J=7.2 Hz), 5.697, 5.433 (ABq, 2H, J=16.4 Hz), 5.334 (s, 2H), 4.460 (d, 1H, J=11.2 Hz), 4.330 (d, 1H, J=11.2 Hz), 2.087 (s, 3H)

LRMS(EI) m/e 392 (M+), 331, 320, 305

HRMS m/e (M+) Calcd: 392.1008, Obsd: 392.1006

In the same manner as in EXAMPLE 38, the compounds (R=H and n=1) of EXAMPLE 63 to 65, expressed by the general formula (I), were prepared.

EXAMPLE R3 1H-NMR(CDCl3 or CDCl3+CD3OD)δ
63 OCONHPh 8.501(s, 1H), 8.228(d, 1H, J=8.0Hz),
8.000(d, 1H, J=8.0Hz), 7.879(t, 1H,
J=7.8Hz), 7.381(s, 1H), 7.714(t, 1H,
J=7.8Hz), 7.361(d, 2H, J=8.0Hz),
7.244(t, 2H, J=7.2Hz), 7.017(t, 1H,
J=7.2Hz), 5.705, 5.561(ABq, 2H,
J=16.8Hz), 5.328(s, 2H), 4.518(d,
1H, J=11.2Hz), 4.395(d, 1H, J=11.2Hz)
64 OCONH i-Pr 9.8022(d, 1H), 8.4071(s, 1H), 8.2465
(d, 1H, J=8.4Hz), 7.9457(d, 1H, J=8.0Hz)
7.8480(t, 1H, J=7.0Hz), 7.7197(s, 1H),
7.6783(t, 1H, J=7.0Hz), 5.7705, 5.4392
(ABq, 2H, J=16.4Hz), 5.4598(s, 2H),
4.4212(d, 1H, J=11.8Hz), 4.2169(d,
1H, J=11.8Hz), 3.7709-3.8068(m, 1H)
1.2605(d, 6H)
65 8.4077(s, 1H), 8.2476(d, 1H, J=8.7Hz) 7.9451(d, 1H, J=7.1Hz), 7.8447(t, 1H) 7.6998(s, 1H), 7.6787(t, 1H), 5.7736, 5.4860(ABq, 2H, J=16.6Hz), 5.3195(s, 2H), 4.5546(d, 1H, J=11.4Hz), 4.3254 (d, 1H, J=11.4Hz), 4.0714(d, 2H, J=1.0Hz), 3.4257(s, 3H)

EXAMPLE 66

Preparation of dl-20-desethyl-20-hydroxymethylcamptothecin

A mixture of methanol (6 ml), water (2 ml) and LiOH.H2O (33 mg, 0.78 mmol) was added to dl-20-desethyl-20-acetoxymethylcamptothecin (140 mg, 0.36 mmol) and the reaction mixture was stirred at room temperature for 1.5 hrs.

The reaction mixture was concentrated under reduced pressure to remove methanol and stirred in an ice bath for 30 mins until the pH of the solution became controlled 3-3.5 with 1N HCl. The solid, so formed, was filtrated, washed with water, isopropanol and ether successively, and under P2O5, dried in vacuum for 3 hrs to give the desired product(83 mg, 66%) as a yellowish white soild.

IR(KBr) 3436, 1743, 1657 cm−1

1H-NMR (400 MHz, CDCl3+DMSO-d6=1:1) δ 8.608 (s, 1H, 8.157 (d, 1H, J=8.0 Hz), 8.106 (s, 1H), 8.050 (d, 1H, J=8.0 Hz), 7.829 (t, 1H, J=7.3 Hz), 7.673 (t, 1H, J=7.3 Hz), 6.741 (s, 1H), 5.441, 5.360 (ABq, 2H, J=16.1 Hz), 5.304 (s, 2H), 3.850-3.89 (m, 1H), 3.681-3.723 (m, 1H)

LRMS(EI) m/e 350 (M+), 320, 306

HRMS m/e (M+) Calcd: 350.0903, Obsd: 350. 0917

In the same manner as in EXAMPLE 39, the compounds (R=H and n=1) of EXAMPLE 67 to 69, expressed by the general formula (I), were prepared.

EXAM
PLE R3 1H-NMR (CDCl3) δ
67 OCH2OCH3 8.397(s, 1H), 8.240(d, 1H, J=8.0Hz),
7.939(d, 1H, J=80Hz), 7.838(t, 1H,
J=8.0Hz), 7.700(s, 1H), 7.670(t, 1H,
J=8.0Hz), 5.713, 5.410(ABq, 2H,
J=16.4Hz), 5.313(s, 2H), 4.626,
4.587(ABq, 2H, J=6.8Hz), 4.187(s,
1H), 3.839(d, d, 2H, J=10.4Hz),
3.315(s, 3H)
68 OCH2OEt 8.4192(s, 1H), 8.2621(d, 1H, J=8.4Hz)
7.9602(d, 1H, J=8.4Hz), 7.8588(t, 1H)
7.7240(s, 1H), 7.6917(t, 1H, J=8.0Hz)
5.7287, 5.4221(ABq, 2H, J=16.3Hz),
5.3344(s, 2H), 4.7030, 4.6508(ABq,
2H, J=6.9Hz), 4.2620(s, 1H), 3.8727(q
2H, J=7.0Hz), 3.6212-3.6628(m, 1H),
3.5079-3.5554(m, 1H), 1.2136(t, 3H,
J=7.0Hz)
69 OCH2OCH2CH2—OCH3 8.3955(s, 1H), 8.1848(d, 1H, J=8.4Hz)
7.9156(d, 1H, J=7.6Hz), 7.8082(t, 1H)
7.7868(s, 1H), 7.6908(t, 1H), 5.6227,
5.3642(ABq, 2H, J=16.4Hz), 5.2757(s,
2H), 4.6619(d, 1H, J=6.9Hz), 4.6218
(d, 1H, J=6.9Hz), 3.8422(dd, 2H,
J=2, 3, 10.0Hz), 3.6112-3.6380(m, 1H),
3.5719-3.5952(m, 1H), 3.4664-3.4924(m,
2H), 3.3192(s, 3H)

Experiment 1: Cytotoxicity of the Compounds According to this Invention

1) Materials

Cancer Cell Lines

In the determination of cytotoxicity, the following cell lines, purchased from ATCC (U.S.A.), were used for the experiments as the target organisms: L1210 (ATCC CCL 219), A172 (ATCC CRL 1620), A427 (ATCC HTB 53), A549 (ATCC CCL185), SK-NEP-1 (ATCC HTB 48), CAOV-3 (ATCC HTB 75), HEC-1-B (ATCC HTB 113), DLD-1 (ATCC CCL 221) and KATO-III (ATCC HTB 103), CAKI-2 (ATCC HTB 47).

Preparation of Culture Medium for Cancer Cells

Distilled water was used for the preparation of culture medium. 1 liter of powdered RPMI 1640 medium was dissolved in distilled water and with addition of NaHCO3 (2.0 g), the resulting solution was stirred. After the pH of the solution was adjusted to 6.8 to 7.4, the medium was filtered by 0.22 μm filter. The fetal bovine serum was thermally treated at 56° C. for 30 mins before use.

Reagents

RPMI 1640 culture medium for cancer cells, fetal bovine serum, sodium bicarbonate and trypsin-EDTA buffer were purchased from Gibco Co. And MTT (3,4,5-dimethylthiazol -2-yl) -2,5-diphenyltetrazolium bromide) and sulforhodamine B(SRB) reagent were obtained from Sigma Co. and other general reagents were of G.R. degree.

Test materials Camptothecin, purchased from Sigma Co., was dissolved in dimethylsulfoxide and with addition of Dulbec co's phosphate buffered saline (DPBS), the concentration of dimethylsulfoxide was adjusted to 10% before use. In case of the synthesized test materials dissolved in dimethylsulfoxide, the concentration of dimethylsulfoxide was also adjusted to 10%, while the other packed with DPBS. The final concentration of dimethyl sulfoxide given to cancer cells was adjusted to less than 1%, which had no influence on the growth of cancer cells.

2) Methods

The cancer cells were grown at 37° C., 5% CO2 in RPMI 1640 medium containing 10% (v/v) fetal serum (FBS), 50 μg/ml gentamicin and 2 g/L sodium bicarbonate. (In order to detach anchorage-dependent cell lines grown by adhering to a culture flask) the medium was removed, washed with PBS one time and with addition of 2 to 3 ml of trypsin-EDTA buffer, the monolayers of cancer cells were wholly covered to stand for the time being. Then, a suspension of the cultured cancer cells was prepared, diluted with a medium and inoculated on 96-well plate so that the number of cells may be the same as described in the following Table 1.

20 μl of sample (PBS solution in a control well) was inoculated to 96-well microplate and cultured for 3 days. After cultivation, the anti-neoplastic activites were measured by SRB assay [Test Scheme 1].

As for anchorage-independent cell such as L1210, cells were inoculated so that the number of cell may also be the same as described in the following Table 1. After being cultured for 2 days, the cytotoxicity against the cells were measured by MTT assay [Test Scheme 2].

The optical density was measured using an automatic microplate reader. The concentration of cell-growth inhibition rate by 50% was calculated by GI50 (computer PCS version 4.1 by Probit method). As per the experiment one time, the mean of optical density on about 2 to 3 wells was used for the calculation.

TABLE 1
Number of inoculated cells per
No. of
inoculated
Cell Line Origin cells (well) Property
(Human)
A427 or A549 Lung 5,000 monolayer
A172 CNS 5,000
DLD-1 Colon 5,000
HEC-1-b Endometrium 5,000
CAOV-3 Ovary 20,000
SK-NEP-1 Kidney 20,000
or CAKi-2
KATO-III Stomach 10,000
(Mice)
L1210 Leukemia 14,000 suspension

TABLE 1
Number of inoculated cells per
No. of
inoculated
Cell Line Origin cells (well) Property
(Human)
A427 or A549 Lung 5,000 monolayer
A172 CNS 5,000
DLD-1 Colon 5,000
HEC-1-b Endometrium 5,000
CAOV-3 Ovary 20,000
SK-NEP-1 Kidney 20,000
or CAKi-2
KATO-III Stomach 10,000
(Mice)
L1210 Leukemia 14,000 suspension

Test Scheme 2: MTT assay
180 μl of cell suspension in medium + 20 μl of sample or PBS
Cultured at 37° C. for 2 days, 5% carbon dioxide.
Added with 50 μl of MTT solution (2 mg/ml in PBS solution).
Cultured for 4 hrs.
Centrifuged at 2,000 rpm for 10 mins.
Removal of supernatant.
Dissolved formazan crystals in DMSO.
Measurement of optical density at 570 nm.
Calculation of GI50

3) Results

The cytotoxicity results of each cell line were as table 2 and 3:

TABLE 2
Example
NO. A427 A172 DLD-1 HEC-1-B CAOV-3 SK-NEP-1 KATO III L1210 MEAN
18 0.14 0.73 0.65 1.8 1.21 0.0077 8.6 0.43 1.83
19 0.31 1.32 0.31 4.7 0.08 0.013 0.29 0.62 1
26 0.23 0.15 0.17 1.37 0.09 0.0031 0.46 2.18 0.35
29 0.07 0.05 0.26 7.68 0.12 0.015 0.21 0.38 1.19
30 0.057 0.065 0.064 1.65 0.025 0.00077 0.024 0.08 0.27
38 0.83 1.63 0.91 20.5 2.3 0.17 3.54 2.3 4.27
39 0.45 1.07 0.76 1.34 0.23 0.018 0.13 0.18 0.57
40 2.4 1.62 2.86 2.57 1.72 0.12 0.4 2.07 1.67
44 2.6 0.028 0.58 10.3 1.8 3.1 2.6 3.32 3
Camptothecin 0.032 0.017 0.047 0.081 0.02 0.00019 0.092 0.024 0.041

TABLE 3
Example
NO. A549 A172 DLD-1 HEC-1-B CAOV-3 SK-NEP-1 KATO III L1210 MEAN
20 0.08 0.54 1.04 4.22 0.023 0.061 1.05 0.73 0.968
21 2.51 11.34 9.68 10.16 2.74 25.16 10.17 5.55 9.66
25 0.94 1.09 5.53 11.44 0.65 7.55 7.86 1.65 4.59
27 3.43 0.4 1.87 7.54 0.47 0.17 0.44 2.34 2.08
28 0.98 11.54 4.35 12.33 2.29 8.89 23.64 6.45 8.81
41 1.15 3.05 13.88 16.23 2.79 1.90 1.33 10.71 6.38
42 0.092 0.58 0.45 1.99 0.78 0.82 8.08 0.6 1.674
43 0.25 1.83 6.84 8.88 0.87 0.99 23.98 2.25 5.74
46 0.56 2.36 4.92 25.27 0.64 3.11 20.88 4.23 7.75
62 0.05 0.6 0.48 5.15 0.32 2.45 3.7 0.67 1.68
63 0.34 1.3 1.99 7.95 0.74 6.17 6.13 1.3 3.24
64 3.28 4.89 10.2 39.75 9.79 51.3 31.48 2.6 19.16
65 2.06 7.43 19.91 20.2 5.45 7.66 53.69 5.75 15.27
66 0.88 2.52 6.24 6.43 0.76 10.79 4.04 1.39 4.13
67 0.2 3.31 0.95 5.4 1.58 2.78 9.17 0.65 3.01
68 1.72 4.55 6.98 14.23 7.18 16.3 16.64 1.39 8.62
69 1.55 1.92 11.32 19.78 2.63 2.13 36.61 9.73 10.71
Camptothecin 0.02 0.05 0.07 0.4 0.01 0.2 0.4 0.06 0.2

Experiment 2: Antitumor activities of the Compounds According to this Invention

The antitumor activities may be usually proven by determining tumor growth inhibitory effects on solid tumor and prolongation effects of life span on artificially tumor-bearing animals.

Antitumor activities were measured through the experiments on prolongation effects of life span against L1210-bearing mice and tumor growth inhibitory effects against B16-bearing mice. To evaluate the antitumor activities on L1210 leukemia, a certain number of L1210 cells (in vitro) was intraperitoneally inoculated for propagation and the L1210 cells in ascites were harvested from animals sacrificed by cervical dislocation on 7th day after tumor was implanted.

To investigate tumor growth inhibitory effects against B16 melanoma, a certain number of B16 cells(in vitro) was subcutaneously inoculated for propagation and tumor cells were resected from animals scrificed by cervical dislocation on 14th day after tumor was implanted.

The following is a detailed description of this EXPERIMENT for antitumor activities.

Experimental Animals

Male BDF1 mice, weighing about 20 grams, were used. Animal rooms were controlled at 23±2° C. and 60±5% relative humidity, under HEPA filter, and maintained in specific pathogen free (SPF).

Experiment 2-1: Prolongation Effects of Life Span against L1210-bearing Mice in Accordance with the Compounds of this Invention.

5×105 of L1210 leukemia cell, obtained in vitro form, were intraperitoneally inoculated in BDF1 mice for propagation. The L1210 tumor cells in ascites were aseptically harvested from BDF1 mice sacrificed by cervical dislocation on 7th day after tumor implantation.

The tumor cells were passaged at least three times prior to use in the test.

5×105 cell were intraperitoneally inoculated into BDF1 mice on day 0 and the sample (0.1 ml/log) were intraperitoneally administration on days 1, 3 and 5. six mice were used for each experimental group.

Antitumor activities were evaluated by the mean survival time of a group of mice and also expressed by the ILS(%) value and the mean animal weights for day 1 and day 5.

Increased Life span (ILS)

ILS(%)={(MST of sample treated group/MST of solvent group)−1}×100

Results

The compound of example 18 given 1st, 3rd and 5th days after the day of tumor inocualtion increased the life span (ILS) of L1210-bearing mice by 33% and 64% at total doses of 10 mg/kg and 50 mg/kg, respectively (Tabel 4).

TABLE 4
Prolongation effects of life aginst L1210 in the
compound of example 18
Dose Survival days 30 days B.W.
Compound (mg/kg) MST ILS(%) survivor Change(g)
Control 9.75 0 0/6 0
Compound of 10 13.00 33 0/6 −0.25
example 18
Compound of 50 16.00 64 0/6 −0.80
example 18

The compound of example 26 given 1st, 3rd and 5th days after the day of tumor inoculation increased the life span (ILS) of L1210-bearing mice by 72% and 75% at total doses of 10 mg/kg and 50 mg/kg, respectively (Table 5).

TABLE 5
Prolongation effects of life against L1210 of the
compound prepared in example 26
Dose Survival days 30 days B.W.
Compound (mg/kg) MST ILS(%) survivor Change(g)
Control 9.125 0 0/6 +1.77
Compound of 10 15.67 72 0/6 −0.09
example 26
Compound of 50 16.00 75 0/6 −0.57
example 26

The compound of example 30 given 1st, 3rd and 5th days after the day of tumor inoculation increased the life span (ILS) of L1210-bearing mice by 42% and 119% at total doses of 10 mg/kg and 50 mg/kg, respectively (Table 6).

TABLE 6
Prolongation effects of life against L1210 of the
compound prepared in example 30
Dose Survival days 30 days B.W.
Compound (mg/kg) MST ILS(%) survivor Change(g)
Control 9.125 0 0/6 +1.77
Compound of 10 13.00 42 0/6 −0.71
example 30
Compound of 50 20.00 119 0/6 −0.57
example 30

Since the compound of example 30 exhibited better dose dependency and ILS(%) than other compound, the inventor et al. tried to elucidate a higher dose level and amounts showing antitumor activities in experimental animals administered with a higher dose.

When the compound of example 30 was given 1st, 3rd and 5th days after the inoculation at total doses of 8.75, 17.5, 35, 70 and 140 mg/kg, the ILS(%) showed 58.7, 79.7, 92.4, 143 and 110%, respectively (Table 7).

TABLE 7
Prolongation effects of life against L1210 of the
compound prepared in example 30 in various dose
Dose Survival days 30 days B.W.
Compound (mg/kg) MST ILS(%) survivor Change(g)
Control 9.875 0 0/6 +1.44
Compound of 8.75 15.67 58.7 0/6 +0.7
example 30
Compound of 17.5 17.75 29.2 0/6 +0.45
example 30
Compound of 35 19.00 92.4 0/6 −0.12
example 30
Compound of 70 24.00 143 0/6 −0.79
example 30
Compound of 140 20.75 110 0/6 −0.93
example 30

When the compound of example 30 was given on day 1, 3 and 5 after the tumor inoculation, the maximum ILS of 143% was obtained at total dose of 70 mg/kg.

The antitumor activity of the compound of example 30 against intraperitoneally-implanted L1210 was evaluated in parallel with that of camptothecin as shown in FIG. 1. The compound of example 30 gave higher ILS(%) and wider range where the effect was siginificant.

Experiment 2-2: Tumor Growth Inhibitory Effects on B16-bearing Mice in Accordance with the Compounds of this Invention

106 of B16 melanoma cell, obtained in vitro form, were subcutaneously in BDF1 mice for propagation. The B16 melanomas were transfered on day 14. The fresh tumors except for necrotized center were aseptically resected from tumor-bearing mice sacrificed by cervical dislocation.

The tumor cells were passaged at least injected three times prior to use in the test.

1 g subcutaneously donor tumor to be subcutaneously was homogenized in cold sterilized saline to give a final concentration of 1 g/10 ml. The 1:10 tumor suspension is injected into all BDF1 mice subcutaneously using 0.2 ml/mouse.

The mice were subcutaneously implanted with such homogenized solution and 7 to 8th day after the tumor implantation, the mice having a certain size of tumors were selected for experiments. Each experimental group were administered with the sample (0.1 ml/10 g) on 8th, 12th and 16th day after the inoculation of tumor. Eight mice were used for each experimental group.

The size of the tumors was calculated by direct measurement of the diameter of the tumors, using the formula.

Tumor size=(a 2 b)/2

Where b is the largest diameter and a is the diameter perpendicular to b and growth curves were thus obtained. (FIG. 2)

The inhibition rate of tumor growth on the basis of tumor size was calculated according to the formula.

Wherein;

IR(%)=(1−TWt/TWc)×100

TWt is the mean tumor volume(weight) of sample-treated groups.

TWc is the mean tumor volume(weight) of control group.

Test Results

When the compound of example 30 was given 8, 12 and 16 days after the tumor inoculation at total doses of 35, 70 and 140 mg/kg , the IR(%) showed 27, 54.8 and 67.72%, respectively (Table 8).

TABLE 8
Tumor growth inhibitory effects against B16
melanoma of the compound prepared in example 30
2. Compound of 3. Compound 4. Compound of
1. Camptothecin example 30 of example 30 example 30
Control 10 mg/kg 35 mg/kg 70 mg/kg 140 mg/kg
Tumor
size
day 8  87.69 ± 13.58  85.95 ± 13.15  86.93 ± 11.34  86.21 ± 10.12 86.94 ± 9.34
day 12 598.50 ± 93.59 458.56 ± 53.87 411.88 ± 71.52 320.06 ± 71.79 328.98 ± 76.57
day 16 2492.75 ± 437.80 1035.98 ± 129.36 1234.65 ± 182.64 870.46 ± 77.27 695.75 ± 82.77
day 20 4194.83 ± 285.66 1775.50 ± 300.91 3061.34 ± 752.34 1897.88 ± 256.22 1353.91 ± 134.36
IR (%) 57.8% 27% 54.8% 67.72%
Tumor
weight
day 20  3.92 ± 0.32  1.61 ± 0.30  2.34 ± 0.44  1.71 ± 0.18  1.11 ± 0.21
IR (%) 59% 40% 56% 71.6%

Futher, 20th day after the compound of example 30 was administered, the percentage of IR on the weight of the incised tumor showed 40, 56 and 71.6%, respectively.

The maximum IR of 67.72% was obtained at total dose of 140 mg/kg. The changes in tumor volumes were outlined in FIG. 2. Such results clearly imply that the compound of example 30 has not only better antitumor activity on ascites tumor and solid type tumor, but also less toxicity and a wide range of safety margin, compared with camptothecin.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4894456Mar 31, 1987Jan 16, 1990Research Triangle InstituteSynthesis of camptothecin and analogs thereof
EP0074770A1Sep 3, 1982Mar 23, 1983Kabushiki Kaisha Yakult HonshaCamptothecin-1-oxide derivatives, process for preparing same, formulations comprising said derivatives and said derivatives for use in producing an anti-tumour effect
EP0088642A2Mar 10, 1983Sep 14, 1983Kabushiki Kaisha Yakult HonshaNew camptothecin derivatives and process for their preparation
EP0540099A1Oct 23, 1992May 5, 1993Glaxo Wellcome Inc.Water soluble camptothecin derivatives
WO1992005785A1Sep 23, 1991Apr 16, 1992Smithkline Beecham CorporationWater soluble camptothecin analogues, processes and methods
Non-Patent Citations
Reference
1Arch. Pharma. (Weinheim) vol. 316, No. 8, pp. 707-712 (1983) Abstract Only.
2English Abstract of JP 6-228141, 1994.*
3Journal of Medicinal Chemistry, vol. 34, pp. 98-107 (1991).
4Journal of Medicinal Chemistry, vol. 36, No. 18, pp. 2689-2700 (1993).
5Monroe E. Wall et al., "The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata", Journal of the American Chemical Society, pp. 3888-3890, Aug. 20, 1966.
6Robert T. Crow et al., "Structural Modifications of Camptothecin and Effects on Topoisomerase I Inhibition", Journal of Medicinal Chemistry, vol. 35, No. 22, pp. 4160-4164, 1992.
7Xie, Bioorg. Med. Chem. Lett. 5, 2189, 1995.*
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6352996 *Feb 8, 2000Mar 5, 2002The Stehlin Foundation For Cancer ResearchLiposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US8076351Jul 12, 2007Dec 13, 2011Indena S.P.A.Camptothecin derivatives with antitumor activity
US20100063082 *Jul 12, 2007Mar 11, 2010Gabriele FontanaCamptothecin derivatives with antitumor activity
EP1433789A1 *Dec 24, 2002Jun 30, 2004Aponetics AGPyrrolopyrazines and their use as selective apoptosis inducers
WO2008011992A1 *Jul 12, 2007Jan 31, 2008Indena S.P.A.Camptothecin derivatives with antitumor activity
Classifications
U.S. Classification514/283, 514/279, 546/41
International ClassificationA61P35/00, C07D491/14, C07D491/147, C07D491/22, A61K31/44
Cooperative ClassificationY02P20/55, C07D491/14
European ClassificationC07D491/14
Legal Events
DateCodeEventDescription
Jul 7, 1997ASAssignment
Owner name: CHONG KUN DANG CORP., KOREA, REPUBLIC OF
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JEW, SANG SUP;LEE, HEE SOON;KIM, JOON KYUM;AND OTHERS;REEL/FRAME:008781/0345
Effective date: 19970430
Apr 16, 2002CCCertificate of correction
Jan 24, 2005FPAYFee payment
Year of fee payment: 4
Jan 26, 2009FPAYFee payment
Year of fee payment: 8
Dec 27, 2012FPAYFee payment
Year of fee payment: 12
Nov 21, 2014ASAssignment
Owner name: CHONG KUN DANG HOLDINGS CORP., KOREA, REPUBLIC OF
Free format text: CHANGE OF NAME;ASSIGNOR:CHONG KUN DANG CORP.;REEL/FRAME:034410/0839
Effective date: 20140818